Skip to main content

Table 1 Standard assessments at treatment start and during follow up

From: Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C

Assessment

Treatment start

Frequency

General

  

 · Complete physical examination

Every 3–6 months

Clinical parameters of neurological disease

  

 · NP-C functional disability scale

Every 6–12 months

 · Video recording

Every 6–12 months

 · Epileptic seizures

Every 6–12 months

 · Narcolepsy/cataplexy

Every 6–12 months

Other measures

  

 · Psychometric evaluations

Every 6–12 months

 · Hearing

Every 6–12 months

 · Abdominal ultrasound

Depending on initial findings

 · Chest X-ray

Initial assessment and depending on clinical evolution

Laboratory parameters

  

 · Liver function

Every 6–12 months

 · Haematology (blood counts)

Every 6–12 months

 · Plasma chitotriosidase (optional)

Initial assessment

Cerebral imaging

  

 · MRI or MRS (magnetic resonance spectroscopy)*

Every 12 months

  1. *Determination of Cho/NAA ratio optional.